Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
In its first public offering in five years, rare disease drug developer BioMarin Pharmaceutical Inc. raised $235.8mm through the sale of 6.5mm shares at $36.28. Since the company’s April 2007 $316mm FOPO, its Kuvan (sapropterin dihydrochloride) phenylketonuria treatment has received FDA approval and its Firdapse (amifampridine) was launched in the EU for Lambert-Eaton myasthenic syndrome (an autoimmune disease). BioMarin also continues to develop its pipeline for other orphan indications such as Pompe disease and Morquio A, both lysosomal storage disorders.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?